BAY 8002

Key Product Details

Product Description

BAY 8002 is a potent dual MCT1/2 inhibitor (IC₅₀ values are 3, 8, and 12 nM at rat (C6), human (DLD-1) and mouse (4T1) MCT1 respectively; IC₅₀ values of human MCT1, MCT2, and MCT4 isoforms recombinantly expressed in X. laevis oocytes are 1, 5 and >500 nM, respectively); suppresses bidirectional lactate transport. Inhibits cellular SNARF-5 fluorescence change (IC₅₀ = 85 nM) in MCT1-expressing DLD-1 cells. Arrests growth and increases intratumor lactate levels of Raji tumor xenografts in mice. Orally bioavailable.

Product Specifications for BAY 8002

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for BAY 8002

The following data is based on the product molecular weight 415.85.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.40 mL	12.02 mL	24.05 mL
5 mM	0.48 mL	2.40 mL	4.81 mL
10 mM	0.24 mL	1.20 mL	2.40 mL
50 mM	0.05 mL	0.24 mL	0.48 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Quanz Preclinical efficacy of the novel monocarboxylate transporter 1 inhibitor BAY-8002 and associated markers of resistance. Mol.Cancer Ther. 2018 PMID: 30115664

Product Documents for BAY 8002